Navigation Links
Market Scope Expects Retina Pharmaceutical Industry to Top $3.5 Billion by 2014

Market Scope has announced the publication of the recently updated 2009 editions of two of its three comprehensive reports on the retinal products industry. According to Market Scope, this is a very exciting time in the retinal products market. New anti-VEGF therapies are successfully treating vision-threatening retinal diseases that, in the recent past, had been largely untreatable. Investigational devices are promising to restore some sight to those who have lost much of their vision. And new diagnostic technologies are allowing the intricate layers of the retina to be visualized with greater clarity and detail than ever before.

St. Louis, MO (PRWEB) May 22, 2009- In the midst of significant advances, demand for retinal treatments is soaring, driven by rapid growth in elderly populations, increases in diabetes, greater access to medical care in emerging economies, and rapidly evolving quality-of-life expectations among aging populations. "The new tools and technologies have mixed with burgeoning demand to create significant opportunity in the rapidly transforming market for retinal pharmaceuticals and devices," according to David Harmon, Market Scope's president.

The retinal pharmaceutical market is no longer a backwater with few products; it has rapidly evolved into one of the largest segments in the ophthalmic pharmaceutical industry. Anti-VEGF therapies have significantly changed the prognosis for those suffering from age-related macular degeneration (AMD). The benefits from these new drugs are dramatic, but much of the commercial opportunity has been constrained by low-cost off-label treatment. Nonetheless, Market Scope expects revenues generated by retinal pharmaceutical sales to climb to $2.8 billion in 2009, while new pipeline products promise significant growth in the coming years.

The more than 50 drug candidates aiming to reshape this market use a variety of new approaches--neuroprotection, kinase inhibition, RNA interference, visual cycle modulation and targeting of the complement cascade--to treat the most devastating retinal diseases such as wet AMD, geographic atrophy, diabetic retinopathy and inherited retinal dystrophies. Although some will fail to meet their goals, others will likely shift the retinal treatment paradigm again. In several years, current market leaders Genentech and Novartis will face competitors such as Regeneron, Sirion Therapeutics, and Neurotech Pharmaceuticals.

Demand for retinal surgery is also growing rapidly, and surgical techniques are quickly evolving to meet patient needs. Technological advances in vitrectomy equipment and photocoagulation lasers, along with new devices such as telescopic IOLs and retinal implants, offer significant growth opportunities. Market Scope forecasts that this market segment will grow at a compounded rate of 9.9 percent through 2014. Alcon and Bausch & Lomb are the current market leaders in this segment.

Advances in diagnostic equipment have laid the groundwork for better diagnosis and monitoring of retinal disease. This is most evident in the new optical coherence technology (OCT) devices that have dramatically improved image resolution and provided real-time cross-sectional images of retinal tissues. Carl Zeiss, Heidelberg, Topcon and Optovue are currently the lead competitors in the rapidly expanding OCT market. Despite tight capital budgets, Market Scope expects growing demand for retinal care and new diagnostic technologies to result in a compounded annual growth of 6.4 percent in the retinal diagnostic equipment segment over the next five years.

Market Scope's three reports on the global retinal market give this dynamic market unmatched visibility and transparency. These reports include detailed analysis of the epidemiology of retinal diseases, demographic trends, commercially available products, pipeline technologies, and companies offering retinal products. Market Scope's analysis divides the world into eight regional markets and includes regional data on units, prices, and revenues over the next five years. Underlying market drivers are also discussed.

Report Descriptions and Table of Contents
2009 Comprehensive Report in the Global Retinal Surgical Device Market
2009 Comprehensive Report on the Global Retinal Pharmaceutical Market
2008 Comprehensive Report on the Global Retinal and Glaucoma Diagnostic Equipment Market

Contact Kristen Harmon for more information or to purchase these and/or other Market Scope reports or call at 314.835.0600 ext 111.

About Market Scope

Market Scope is recognized as the leading source for accurate and timely industry information in ophthalmology. We have been conducting primary research and producing comprehensive reports on ophthalmic markets since 1996. Our data, analysis, and forecasts serve as starting points for many annual planning cycles, strategic plans, acquisition analysis, and return on investment decisions in the industry. In addition, our information is routinely included in annual reports, SEC filings, and investor presentations by leading ophthalmic companies.

# # #

Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
4. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
5. Sodexho, Inc. Announces Patrick E. Connolly as Market President & COO
6. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Paramount Acquisition Corp. Announces Chem Rx Expansion into Albany, New York Market
9. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
10. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
11. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
Post Your Comments:
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from reveals that behind the ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
Breaking Medicine Technology: